US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Articles published by Humacyte, Inc

News headline image
Humacyte to Present at the Piper Sandler 35th Annual Healthcare Conference
From Humacyte, Inc
Via GlobeNewswire
Tickers HUMA
News headline image
Humacyte Announces Two Presentations at the VEITHsymposium® of Positive Clinical Results of the Human Acellular Vessel™ (HAV™) in the Treatment of Vascular Trauma
From Humacyte, Inc
Via GlobeNewswire
Tickers HUMA
News headline image
Humacyte Third Quarter 2023 Financial Results and Business Update
From Humacyte, Inc
Via GlobeNewswire
Tickers HUMA
News headline image
Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 9, 2023
From Humacyte, Inc
Via GlobeNewswire
Tickers HUMA
News headline image
Humacyte Publishes Preclinical Results Showing Human Acellular Vessel™ (HAV™) Patency as Modified Blalock–Taussig–Thomas Shunt in Juvenile Primate Model
From Humacyte, Inc
Via GlobeNewswire
Tickers HUMA
News headline image
Humacyte to Present at the Cantor Global Healthcare Conference
From Humacyte, Inc
Via GlobeNewswire
Tickers HUMA
News headline image
Humacyte to Host In-Person KOL Event at the New York EDITION on September 20, 2023
From Humacyte, Inc
Via GlobeNewswire
Tickers HUMA
News headline image
Humacyte Announces Positive Top Line Results from Phase 2/3 Trial of Human Acellular Vessel™ (HAV™) in Treatment of Patients with Vascular Trauma
From Humacyte, Inc
Via GlobeNewswire
Tickers HUMA
News headline image
Humacyte to Announce Top Line Data from Phase 2/3 V005 Trial in Vascular Trauma Evaluating its Human Acellular Vessel™ (HAV™) Tuesday, September 12, 2023 at 8:00 AM ET
From Humacyte, Inc
Via GlobeNewswire
Tickers HUMA
News headline image
Results From Mayo Clinic Clinical Study of Humacyte’s Human Acellular Vessel™ (HAV™) in Treatment of Patients with Chronic Limb Ischemia Presented at Midwestern Vascular Conference
From Humacyte, Inc
Via GlobeNewswire
Tickers HUMA
News headline image
Humacyte Second Quarter 2023 Financial Results and Business Update
From Humacyte, Inc
Via GlobeNewswire
Tickers HUMA
News headline image
Humacyte Announces Fourth Quarter and Year End 2022 Financial Results and Business Update
From Humacyte, Inc
Via GlobeNewswire
Tickers HUMA
News headline image
Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 24, 2023
From Humacyte, Inc
Via GlobeNewswire
Tickers HUMA
News headline image
Humacyte to Present at Upcoming Investor Conferences in March
From Humacyte, Inc
Via GlobeNewswire
Tickers HUMA
News headline image
Humacyte Publication in the Journal of Vascular Surgery – Vascular Science Reports the Human Acellular Vessel™ (HAV™) Remains Durable at Six Years in Patients with Peripheral Artery Disease
From Humacyte, Inc
Via GlobeNewswire
Tickers HUMA
News headline image
Humacyte Hosting Key Opinion Leader Webinar on Vascular Trauma: Ukrainian Surgeons Discuss Use of Human Acellular Vessels™ (HAV™) in Wartime
From Humacyte, Inc
Via GlobeNewswire
Tickers HUMA
News headline image
Humacyte Human Acellular Vessel™ (HAV™) Ukraine Humanitarian Results to be Presented at Multiple Vascular Conferences in December 2022
From Humacyte, Inc
Via GlobeNewswire
Tickers HUMA
News headline image
Humacyte to Present at the 34th Annual Piper Sandler Healthcare Conference
From Humacyte, Inc
Via GlobeNewswire
Tickers HUMA
News headline image
Humacyte Third Quarter 2022 Financial Results and Business Update
From Humacyte, Inc
Via GlobeNewswire
Tickers HUMA
News headline image
Humacyte Presents Six-Month Human Acellular Vessel™ (HAV™) Coronary Artery Bypass Graft (CABG) Data at the American Heart Association Scientific Sessions 2022 Meeting
From Humacyte, Inc
Via GlobeNewswire
Tickers HUMA
News headline image
Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 10, 2022
From Humacyte, Inc
Via GlobeNewswire
Tickers HUMA